Skip to content
Home
Company
About Us
Leadership
Board of Directors
Advisory Board
Pipeline
Biond Pipeline
BND-22
BND-67
BND-35
Clinical Trials
BND-22
BND-67
BND-35
News
Events
Press
Publications
Contact
Home
Company
About Us
Leadership
Board of Directors
Advisory Board
Pipeline
Biond Pipeline
BND-22
BND-67
BND-35
Clinical Trials
BND-22
BND-67
BND-35
News
Events
Press
Publications
Contact
Home
Company
About Us
Leadership
Board of Directors
Advisory Board
Pipeline
Biond Pipeline
BND-22
BND-67
BND-35
Clinical Trials
BND-22
BND-67
BND-35
News
Events
Press
Publications
Contact
Home
Company
About Us
Leadership
Board of Directors
Advisory Board
Pipeline
Biond Pipeline
BND-22
BND-67
BND-35
Clinical Trials
BND-22
BND-67
BND-35
News
Events
Press
Publications
Contact
News
Publications
Publications
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
Journal for ImmunoTherapy of Cancer / Sep 22, 2022
BND-22, a first-in-class, anti-ILT2 monoclonal antibody inhibits the immunosuppressive effects of HLA-G and enhances anti-tumor activity of immune cells in preclinical in vitro, ex vivo, and in vivo models
Poster Presentations at AACR 2020 Virtual Annual Meeting
Poster Presentation With Sanofi presenting Pre-Clinical Translational Data of SAR444881 (BND-22)
ASCO 2022 Annual Meeting
